A cancer vaccine more than doubled the survival time of people with the most common and deadly type of brain tumor, U.S. researchers said.
The vaccine, made by Avant Immunotherapeutics and licensed by drug giant Pfizer, enlists the help of the immune system to attack the tumor.
Researchers treated 23 patients with a type of brain tumor called glioblastoma multiforme. They have lived, on average, 33 months, said Dr. John Sampson of Duke University, who presented the study at a meeting of the American Society of Clinical Oncology in Chicago.
"That is almost unheard of," Sampson said in an interview. "We have one woman who has gone on to have two babies now," Sampson said.
Patients given standard therapy alone lived on average 14 months. It also took far longer for tumors to grow back after surgery.
In people treated with the vaccine, this so-called time to progression was 16.6 months, more than double the usual six months.
Glioblastoma multiforme, a serious form of brain tumor of a type known as a glioma, kills half its victims within a year and patients rarely survive more than three years.
Massachusetts Democratic Sen. Edward Kennedy was diagnosed with a malignant glioma last month and the vaccine could be one among several options he might try, Sampson said.
"Kennedy may well be a candidate. We don't know if he is interested at this point," Sampson said in an interview.
Kennedy's office said the senator would be undergoing surgery on Monday at Duke in Durham, North Carolina.
Former Yankees baseball star Bobby Murcer is already being treated with the vaccine.
The vaccine targets a mutation of a very common structure known as a receptor on the tumor cells, the epidermal growth factor receptor. This mutation is only found in cancer, not in normal tissues.
"It is completely tumor-specific," Sampson said in a telephone interview.
The vaccine is coupled with a chemotherapy drug called temozolomide, sold by Schering-Plough under the brand name Temodar, which is thought to boost the immune response.
"The immune responses these patients are getting are phenomenal," Sampson said.
One of the worries about immune therapies is that the immune system may start attacking itself. So far, that has not happened, Sampson said.
A second study of the vaccine that followed a slightly different design and dosing schedule in 21 patients resulted in a median survival time of 26 months, compared to the typical 15-month survival for similar patients who just got standard therapy.
A larger randomized study is currently enrolling patients at 24 sites across the United States.
The results have been enough to attract the interest of Pfizer Inc, which in April agreed to pay a total of more than $400 million for rights to market the vaccine.
Pfizer, whose stock is at a 10-year-low, is in need of a big win.
"This is probably one of the biggest if not the biggest immunotherapy deals that has been made," Sampson said. "If this works, I think there will be more investment in vaccines," he said.
About 22,000 malignant tumors of the brain or spinal cord will be diagnosed this year in the United States, and about 13,000 people will die from them, according to the American Cancer Society.